

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1 (Original). A peptide originating from mammalian IL1 $\beta$  or TNF $\alpha$  cytokines, homologous which has more than 80% amino acid homology to one of the following peptides of human IL1 $\beta$  or TNF $\alpha$  cytokines:

80 ~~ISRIAVSYQTKVNLLS~~ 95 (SEQ ID NO:2)

140 DYLDFAESGQVY 150 (SEQ ID NO:5);

3 VKSLNCTLRDSQQKSL 18 (SEQ ID NO:7);

45 SFVQGEESNDKIP 57 (SEQ ID NO:8);

89 NYPKKKMEKRFVFNKIEI 106 (SEQ ID NO:9);

121 YISTSQAENMPVFLG 135 (SEQ ID NO:4); and

143 ITDFTMQFVSS 153 (SEQ ID NO:10).

Claim 2 (Cancelled).

3 (Original). A peptide according to claim 1, wherein the human TNF $\alpha$  cytokine peptide sequence is DYLDFAESGQVY (SEQ ID NO:5)

4 (Withdrawn). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is VKSLNCTLRDSQQKSL (SEQ ID NO:7).

5 (Withdrawn). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is SFVQGEESNDKIP (SEQ ID NO:8).

6 (Withdrawn). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is NYPKKKMEKRFVFNKIEI (SEQ ID NO:9).

7 (Withdrawn). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is YISTSQAENMPVFLG (SEQ ID NO:4).

8 (Withdrawn). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine sequence is ITDFTMQFVSS (SEQ ID NO:10).

Claim 9 (Cancelled).

10 (Previously Presented). A derivative of the peptide according to claim 1.

11 (Previously Presented). A peptide according to claim 1 characterized in that it consists of less than 30 amino acids.

12 (Currently Amended). A derivative of a peptide as defined in claim 1 by ~~deletion, substitution, addition, cyclization, stereochemical modification (use of D series amino acids) or functionalization (such as acylation) of one or more amino acids of said peptide.~~

13 (Currently Amended). An immunogenic compound characterized in that it comprises a peptide ~~or peptide derivative~~ as defined in claim 1, it being understood that it comprises no other epitopes of said cytokine and in that it is capable of generating in a subject antibodies recognizing the native cytokine.

14 (Currently Amended). ~~A~~An immunizing composition, comprising the immunogenic compound of claim 13 and an adjuvant~~peptide or peptide derivative or immunogenic compound as defined in claim 1 for use in a method for preventive or therapeutic treatment of the human body.~~

Claims 15 and 16 (Cancelled).

17 (Currently Amended). A pharmaceutical composition which contains at least one peptide ~~or peptide derivative or immunogenic compound~~ as defined in claim 1 as active ingredient.

18 (Withdrawn). Monoclonal or oligoclonal antibody specific to a peptide defined in claim 1.

Claim 19 (Cancelled).

20 (Withdrawn). A method for the treatment of a disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ , comprising administering to a patient in need thereof an antibody as defined in claim 18 to treat the disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ .

21 (Withdrawn-Currently Amended). A method for the treatment or prevention of diseases associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ , comprising administering to a patient in need thereof a peptide ~~or peptide derivative or immunogenic compound~~ as defined in

Appln. No. 10/590,905  
Amd. dated December 14, 2009  
Reply to Office Action of October 13, 2009

claim 1 to treat or inhibit the disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ .